Clostridium difficile 30 years on: what has, or has not, changed and why?

https://doi.org/10.1016/S0924-8579(09)70008-1Get rights and content

Abstract

The report of clindamycin-associated colitis in 1974 by Tedesco et al. [Ann Intern Med 81: 429–33] stimulated an intense search for the cause of this severe complication of antibiotic use. The search culminated in early 1978 in the publication of a series of papers within 3 months that identified the causative agent as Clostridium difficile and its accompanying toxins. Thirty years later we are in the midst of a resurgence of C. difficile infection (CDI) in North America and Europe that is greater than ever previously reported and for which morbidity and mortality appear to be higher than ever seen in the past. The purpose of this review is to highlight the discoveries of the past 30 years that, in my view, have brought us to our current level of understanding of the pathogenesis, prevention and treatment of CDI, and to suggest why a disease thought to be managed so well 30 years ago could now be causing more morbidity and mortality than ever before. In the 21st century the focus should be on better understanding the relationship between the C. difficile organism and the host at the mucosal level, so that biotherapeutic and vaccine strategies for the prevention of CDI can be developed.

References (92)

  • DG Teasley et al.

    Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

    Lancet

    (1983)
  • R Fekety et al.

    Treatment of antibioticassociated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens

    Am J Med

    (1989)
  • M Tvede et al.

    Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

    Lancet

    (1989)
  • L Kyne et al.

    Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

    Lancet

    (2001)
  • D Drudy et al.

    Human antibody response to surface layer proteins in Clostridium difficile infection

    FEMS Immunol Med Microbiol

    (2004)
  • CP Kelly et al.

    Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding

    Gastroenterology

    (1992)
  • ZD Jiang et al.

    Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea

    Clin Gastroenterol Hepatol

    (2007)
  • S Sougioultzis et al.

    Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

    Gastroenterology

    (2005)
  • JMT Finney

    Gastroenterostomy for cicatrizing ulcer of the pylorus

    Johns Hopkins Med J

    (1893)
  • DM Hambre et al.

    The toxicity of penicillin as prepared for clinical use

    Am J Med Sci

    (1943)
  • JD Pettet et al.

    Postoperative pseudomembranous enterocolitis

    Surg Gynecol Obstet

    (1954)
  • SJM Goulston et al.

    Pseudo-membranous colitis

    Gut

    (1965)
  • FJ Tedesco et al.

    Clindamycin-associated colitis. A prospective study

    Ann Intern Med

    (1974)
  • JC Hall et al.

    Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis

    Am J Dis Child

    (1935)
  • Hafiz S. Clostridium difficile and its toxins [PhD Thesis]. Leeds: Department of Microbiology, University of Leeds;...
  • HE Larson et al.

    Undescribed toxin in pseudomembranous colitis

    Br Med J

    (1977)
  • JG Bartlett et al.

    Antibioticassociated pseudomembranous colitis due to toxin-producing clostridia

    N Engl J Med

    (1978)
  • WL George et al.

    Aetiology of antimicrobial-agent-associated colitis

    Lancet

    (1978)
  • JG Bartlett

    Introduction

  • DM Lyerly et al.

    Biological activities of toxins A and B of Clostridium difficile

    Infect Immun

    (1982)
  • DM Lyerly et al.

    Effects of Clostridium difficile toxins given intragastrically to animals

    Infect Immun

    (1985)
  • M Riegler et al.

    Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro

    J Clin Invest

    (1995)
  • I Just et al.

    Glucosylation of Rho proteins by Clostridium difficile toxin B

    Nature

    (1995)
  • I Just et al.

    The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile

    J Clin Invest

    (1995)
  • CH Dove et al.

    Molecular characterization of the Clostridium difficile toxin A gene

    Infect Immun

    (1990)
  • C von Eichel-Streiber et al.

    Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B

    Med Microbiol Immunol

    (1990)
  • T Hundsberger et al.

    Transcription analysis of the genes tcdA E of the pathogenicity locus of Clostridium difficile.

    Eur J Biochem

    (1997)
  • N Mani et al.

    Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor

    Proc Natl Acad Sci USA

    (2001)
  • S Matamouros et al.

    Clostridium difficile toxin expression is inhibited by the novel regulator TcdC

    Mol Microbiol

    (2007)
  • RA Browne et al.

    The protective effect of vancomycin on clindamycin-induced colitis in hamsters

    Johns Hopkins Med J

    (1977)
  • TW Chang et al.

    Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients

    Infect Immun

    (1978)
  • HE Larson et al.

    Epidemiology of experimental enterocecitis due to Clostridium difficile

    J Infect Dis

    (1980)
  • KH Wilson et al.

    Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile

    J Infect Dis

    (1983)
  • SP Borriello et al.

    Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains

    J Med Microbiol

    (1985)
  • ME Mulligan et al.

    Contamination of a hospital environment by Clostridium difficile

    Curr Microbiol

    (1979)
  • KH Kim et al.

    Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis

    J Infect Dis

    (1981)
  • Cited by (57)

    • Antibiotic resistance of clinical isolates of Clostridioides difficile in China and its association with geographical regions and patient age

      2019, Anaerobe
      Citation Excerpt :

      Clostridium difficile, reclassified as Clostridioides difficile [1], is the key precipitant of antibiotic-associated diarrhea. The use of antibiotics, especially clindamycin, third-generation cephalosporins, and fluoroquinolones, have been associated with the development of Clostridium difficile infection (CDI), which disrupts the normal intestinal microbiota and creates conditions suitable for proliferation of C. difficile [2]. Epidemic C. difficile PCR ribotype 027 (B1/NAP1/027) has been shown to have elevated resistance to fluoroquinolones, is associated with increased disease severity and mortality, and has caused several outbreaks in Europe and North America [3].

    • Local outbreak of Clostridioides difficile PCR-Ribotype 018 investigated by multi locus variable number tandem repeat analysis, whole genome multi locus sequence typing and core genome single nucleotide polymorphism typing

      2019, Anaerobe
      Citation Excerpt :

      In Europe, the estimated number of healthcare-associated CDI cases in 2013 was 126,000 per year with a 3% attributable mortality [5]. The incidence of CDI has been increasing worldwide partly due to the emergence of an epidemic strain (NAP1/027/BI) responsible for large outbreaks of severe CDI in the last few years [6,7]. Recent European surveillance has shown that NAP1/027/BI is still predominant and represents 19% of all isolates but a wide variation of ribotype distribution is observed across countries [8].

    • How to: diagnose infection caused by Clostridium difficile

      2018, Clinical Microbiology and Infection
    • Antimicrobial Agents

      2018, Principles and Practice of Pediatric Infectious Diseases
    View all citing articles on Scopus
    View full text